Alani Nu
Total Consideration
$2.06B
Purchase-Price Allocation
Goodwill
$734.4M
Intangibles
$1.22B
Contingent Earn-Out
$25.0M
2 years of history · ending 2025-12-31 · SEC EDGAR
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.
Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.
Effective Rate Trend
| Reconciliation Line | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Federal Statutory Rate | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% |
| State & Local Income Taxes | 4.40% | -12.50% | -3.90% | 4.70% | 6.20% | 3.30% |
| Foreign Rate Differential | — | — | 0.00% | 0.10% | 3.30% | — |
| Other Adjustments | — | — | — | — | — | — |
| FDII Deduction | — | — | — | — | — | 1.20% |
| SBC (Nondeductible) | — | — | — | -3.40% | -5.20% | 1.70% |
| Valuation Allowance Change | — | — | — | -0.30% | -0.70% | — |
| Tax Law Change | — | — | — | — | — | — |
| Effective Tax Rate | 2.30% | 1.97% | -22.70% | 22.20% | 25.70% | 13.60% |
Cash vs Accrual
| Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Income Tax Expense (Accrual) | $116.0K | −$8.0M | $34.6M | $64.9M | $50.0M | $17.0M |
| Income Taxes Paid (Cash) | — | — | — | — | — | $64.2M |
Per-deal acquisition disclosures sourced from us-gaap:BusinessAcquisitionAxis dimensional XBRL. Each card surfaces the deal's purchase-price allocation (goodwill vs intangibles vs liabilities), contingent consideration (unpaid earn-outs), and pro-forma combined-entity numbers. Probability-of-Success (PoS) factor on biotech targets is the ASC 805 contingent-consideration valuation — higher = closer to commercialization, higher implied target value.
Total Consideration
$2.06B
Purchase-Price Allocation
Goodwill
$734.4M
Intangibles
$1.22B
Contingent Earn-Out
$25.0M
Total Consideration
$307.6M
Purchase-Price Allocation
Goodwill
$109.8M
Intangibles
$181.5M
Purchase-Price Allocation
Goodwill
$58.3M
Pro-Forma Combined Entity
Revenue
$3.00B
Net Income
+$218.7M
Per-category restructuring disclosures sourced from us-gaap:RestructuringCostAndReserveAxis dimensional XBRL. Negative charges indicate reversals of prior accruals (a sign the original estimate was too aggressive — flattering current-period earnings).
As of 2025-12-31
| Category | Class | P&L Charge | Cash Paid | Reserve Balance |
|---|---|---|---|---|
| Contract Termination | Contract Termination | +$328M | $70M | — |
Phase 1: currency selection stored in the URL. Conversion ships in Phase 2 (see ADR-0003).